New Mexico, USA 06/15/2015 –Indica Labs, Inc. and Advanced Cell Diagnostics (ACD) announce the signing of a co-marketing partnership agreement to advance quantitative analysis in ACD’s RNAscope Pharma Assay Services.
Under the terms of the agreement, ACD will utilize Indica Labs’ HALO™ image analysis software in its Pharma Assay Services (PAS) for high-throughput, precision interpretation of ACD’s RNAscope ISH assays for quantitative, single molecule in situ detection of RNA biomarkers. ACD will enhance the offerings of its PAS by employing HALO’s analytical capabilities in target validation and biomarker development studies involving single-target and multiplexed RNAscope. Additionally, ACD will utilize newly developed HALO algorithms for quantification of complex RNAscope expression data.
Indica CEO Steven Hashagen remarked, “We are pleased to form this partnership with ACD. The RNAScope assay complemented by HALO image analysis represents the industry’s most comprehensive ISH quantification capabilities including multiplex chromogenic RNA ISH, multiplex RNA FISH, cell by cell expression profiles, and automated differentiation of discrete cell populations within tissue. These capabilities will enable ACD and their clients to unlock the full potential of RNA based biomarkers.”
“ACD Chief Commercial Officer Tom O’Lenic stated, “ACD provides assays services to a wide range of biopharma with an expanding range of needs all relating to understanding target and biomarker expression in the context of disease pathology. This is a great fit between the multiplexed, molecular resolution of RNAscope and HALO, a multiplexed quantification software.” Mr. O’Lenic, went on to say, “Indica’s HALO will enable us to maximize the information value that we deliver in our services, as well as the speed with which we can deliver quantitative analysis to our PAS clients.”
About Advanced Cell Diagnostics
Advanced Cell Diagnostics, Inc. (ACD) is a leader in the field of molecular pathology, enabling tissue-based, quantitative target and biomarker assays. The company’s products and services are based on its proprietary RNAscope® technology, the most sensitive and clinically robust automated RNA in situ hybridization platform capable of chromogenic, fluorescence and multiplexed detection and quantification of RNA biomarkers in situ with single molecule resolution. RNAscope is an established platform at all leading global pharmaceutical companies, world leading academic institutions and the majority of biotechnology companies for target validation, safety assessment and biomarker development in oncology and other major therapeutic areas. ACD’s Pharma Assay Services provide the context in which ACD supports preclinical and clinical therapeutic development. RNAscope is now being used for patient selection in late-stage clinical trials, which may be the basis for future companion diagnostic tests. ACD is also developing proprietary diagnostic tests for cancer management. Learn more about ACD and RNAscope technology at www.acdbio.com.
About Indica Labs, Inc.
Indica Labs is a leading provider software for quantitative evaluation of pathology images. Indica’s HALO™ image analysis platform provides a unique combination of precision, performance, scalability, and usability. Indica’s broad range of industry leading tissue-specific image analysis algorithms can be used in a variety of truly integrated digital pathology environments, allowing pharmaceutical, healthcare, and research organizations worldwide to apply high-throughput image quantification in areas such as neuroscience, metabolism, oncology, toxicological pathology and more. For more information, please visit http://indicalab.com.